MDMA, more commonly known as ecstasy or molly, was used in two late-stage studies by Lykos Therapeutics to determine its potential to treat PTSD. The drug is intended to be used in combination with psychological intervention, including therapy and other supportive services.
The panel of advisers will meet June 4 to deliberate on the MDMA-assisted therapy. No psychedelic-based therapy has been approved yet in the U.S., though many companies have tested such drugs for use treating a range of mental health disorders.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
